Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/2855
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | BUYSE, Marc | - |
dc.contributor.author | Piedbois, P | - |
dc.contributor.author | Piedbois, Y | - |
dc.contributor.author | Carlson, RW | - |
dc.date.accessioned | 2007-11-20T10:11:04Z | - |
dc.date.available | 2007-11-20T10:11:04Z | - |
dc.date.issued | 2000 | - |
dc.identifier.citation | ONCOLOGY-NEW YORK, 14(3). p. 437-443 | - |
dc.identifier.issn | 0890-9091 | - |
dc.identifier.uri | http://hdl.handle.net/1942/2855 | - |
dc.description.abstract | Meta-analysis is a systematic, quantitative approach to the combination of data from several clinical trials that address the same question. This analytic approach can help resolve questions that remain unclear from the results of individual trials. Meta-analysis is of particular interest in oncology because of the small differences in efficacy between therapeutic alternatives. The large number of patients included in meta-analyses permit small to moderate benefits of a treatment to be reliably detected and larger treatment benefits to Be quantified more accurately. Despite these apparent benefits, the use of meta-analysis has met with a great deal of resistance and has generated much controversy in clinical journals, After a brief description of the basic methods of conducting meta-analyses, this article will explore both their advantages and disadvantages. | - |
dc.language.iso | en | - |
dc.publisher | P R R INC | - |
dc.title | Meta-analysis: Methods, strengths, and weaknesses | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 443 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 437 | - |
dc.identifier.volume | 14 | - |
local.format.pages | 7 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Int Inst Drug Dev, B-1050 Brussels, Belgium. Limburgs Univ Ctr, Brussels, Belgium. Hop Henri Mondor, Dept Oncol, F-94010 Creteil, France. Assoc Europeenne Rech Oncol, Creteil, France. Stanford Univ, Med Ctr, Div Oncol, Palo Alto, CA 94304 USA.Buyse, M, Int Inst Drug Dev, 430 Ave Louise,B14, B-1050 Brussels, Belgium. | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.bibliographicCitation.oldjcat | A1 | - |
dc.identifier.isi | 000090128900022 | - |
item.fulltext | No Fulltext | - |
item.accessRights | Closed Access | - |
item.fullcitation | BUYSE, Marc; Piedbois, P; Piedbois, Y & Carlson, RW (2000) Meta-analysis: Methods, strengths, and weaknesses. In: ONCOLOGY-NEW YORK, 14(3). p. 437-443. | - |
item.validation | ecoom 2001 | - |
item.contributor | BUYSE, Marc | - |
item.contributor | Piedbois, P | - |
item.contributor | Piedbois, Y | - |
item.contributor | Carlson, RW | - |
Appears in Collections: | Research publications |
WEB OF SCIENCETM
Citations
21
checked on Aug 13, 2024
Page view(s)
28
checked on May 23, 2023
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.